Defining CDK12 as a tumor suppressor and therapeutic target in mouse models of tubo-ovarian high-grade serous carcinoma
Proceedings of the National Academy of Sciences · 17.06.2025 · 122 (24)
DOI: 10.1073/pnas.2426909122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 12.06.2025. Verfasst von Jean Ching-Yi Tien und 30 weiteren Autor:innen. Beteiligte Einrichtung: Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Cyclin-Dependent Kinases, Cystadenocarcinoma, Serous. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HHS | NIH | National Cancer Institute (NCI), NCI NIH HHS, U.S. Department of Defense (DOD).
Abstract (Originalsprache)
Ovarian cancer is the sixth leading cause of cancer death among American women, with most fatalities attributable to tubo-ovarian high-grade serous carcinoma (HGSC). This malignancy usually develops resistance to conventional chemotherapy, underscoring the need for robust preclinical models to guide the development of novel therapies. Here, we introduce an HGSC mouse model generated via Ovgp1 -driven Cre recombinase effecting CRISPR/Cas9-mediated deletion of Trp53, Rb1 , and Nf1 tumor suppressors in mouse oviductal epithelium ( m-sgPRN model). Cyclin-dependent kinase 12 (CDK12) inactivation—frequently observed in human HGSC—is associated with poorer outcomes, DNA damage accumulation (including tandem duplications), and increased tumor immunogenicity. In our system, coablation of Cdk12 ( m-sgPRN;Cdk12KO ) recapitulated hallmark features of HGSC, while accelerating tumor progression and reducing survival. In a conventional (Cre-lox-mediated) Trp53/Nf1/Rb1 triple knockout model with concurrent Cdk12 ablation ( PRN ; Cdk12KO mice), we observed T cell–rich immune infiltrates mirroring those seen clinically. We established both models as subcutaneous or intraperitoneal syngeneic allografts of CDK12 -inactivated HGSC that exhibited sensitivity to immune checkpoint blockade. Furthermore, a CRISPR/Cas9 synthetic lethality screen in PRN;Cdk12KO -derived cell lines identified CDK13—an essential paralog of CDK12—as the most depleted candidate, confirming a previously reported synthetic lethal interaction. Pharmacologic CDK13/12 degradation (employing YJ1206) demonstrated enhanced efficacy in cell lines derived from both m-sgPRN;Cdk12KO and PRN ; Cdk12KO models. Our results define CDK12 as a key tumor suppressor in tubo-ovarian HGSC and highlight CDK13 targeting as a promising therapeutic approach in CDK12 -inactive disease. Additionally, we have established valuable in vivo resources to facilitate further investigation and drug development in this challenging malignancy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109.
- Department of Pathology, University of Michigan, Ann Arbor, MI 48109.
- Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109.
- State Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, People's Republic of China.
- Rogel Cancer Center, University of Michigan, Ann Arbor, MI 48109.
- Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI 48109.
ORCID-Profile: Jean Ching-Yi Tien, Yuping Zhang, Rahul Mannan, Caleb Cheng, Rui Wang, Yuanyuan Qiao, Zhen Wang, Jonathan Chou, Ke Ding, Arul M Chinnaiyan
Förderung
- HHS | NIH | National Cancer Institute (NCI)
- NCI NIH HHS
- U.S. Department of Defense (DOD)
- NIGMS NIH HHS
- MOST | National Natural Science Foundation of China (NSFC)
Zitieren
APA
Tien, J. C., Zhai, Y., Wu, R., Zhang, Y., Chang, Y., Cheng, Y., Todd, A. J., Wheeler, C. E., Li, S., Mannan, R., Cheng, C., Magnuson, B., Cruz, G., Cao, Y., Mahapatra, S., Stolfi, C., Cao, X., Su, F., Wang, R., …, & Chinnaiyan, A. M. (2025). Defining CDK12 as a tumor suppressor and therapeutic target in mouse models of tubo-ovarian high-grade serous carcinoma. Proceedings of the National Academy of Sciences, 122(24). https://doi.org/10.1073/pnas.2426909122
Vancouver
Tien JC, Zhai Y, Wu R, Zhang Y, Chang Y, Cheng Y, et al. Defining CDK12 as a tumor suppressor and therapeutic target in mouse models of tubo-ovarian high-grade serous carcinoma. Proceedings of the National Academy of Sciences. 2025;122(24). doi:10.1073/pnas.2426909122
BibTeX
@article{Tien2025,
author = {Tien, Jean Ching-Yi and Zhai, Yali and Wu, Rong and Zhang, Yuping and Chang, Yu and Cheng, Yunhui and Todd, Abigail J and Wheeler, Christina E and Li, Shuqin and Mannan, Rahul and Cheng, Caleb and Magnuson, Brian and Cruz, Gabriel and Cao, Yizhi and Mahapatra, Somnath and Stolfi, Carmine and Cao, Xuhong and Su, Fengyun and Wang, Rui and Yang, Jianzhang and Zhou, Licheng and Qiao, Yuanyuan and Xiao, Lanbo and Cieslik, Marcin and Wang, Xiaoju and Wang, Zhen and Chou, Jonathan and Fearon, Eric R and Ding, Ke and Cho, Kathleen R and Chinnaiyan, Arul M},
title = {Defining CDK12 as a tumor suppressor and therapeutic target in mouse models of tubo-ovarian high-grade serous carcinoma},
journal = {Proceedings of the National Academy of Sciences},
year = {2025},
volume = {122},
number = {24},
doi = {10.1073/pnas.2426909122}
}
EUVIMED